U.S. Capital Wealth Advisors LLC Decreases Stock Holdings in Stryker Corporation $SYK

U.S. Capital Wealth Advisors LLC lowered its stake in shares of Stryker Corporation (NYSE:SYK) by 32.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,464 shares of the medical technology company’s stock after selling 1,169 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Stryker were worth $975,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in SYK. Goodman Advisory Group LLC bought a new stake in Stryker in the 1st quarter worth approximately $32,000. City Holding Co. grew its holdings in shares of Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after acquiring an additional 74 shares during the period. Ransom Advisory Ltd purchased a new stake in Stryker during the first quarter valued at $37,000. Smallwood Wealth Investment Management LLC bought a new position in Stryker in the first quarter valued at about $40,000. Finally, Cornerstone Planning Group LLC boosted its position in Stryker by 46.0% in the first quarter. Cornerstone Planning Group LLC now owns 127 shares of the medical technology company’s stock worth $45,000 after purchasing an additional 40 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Trading Down 0.7%

Shares of SYK stock opened at $370.92 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The stock has a fifty day simple moving average of $386.51 and a two-hundred day simple moving average of $378.95. The firm has a market capitalization of $141.81 billion, a PE ratio of 49.13, a PEG ratio of 2.69 and a beta of 0.93. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Truist Financial set a $415.00 price objective on shares of Stryker and gave the stock a “hold” rating in a research note on Monday, August 4th. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Needham & Company LLC lifted their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Rothschild & Co Redburn initiated coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective for the company. Finally, BTIG Research reiterated a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Fourteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $430.33.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.